Tourmaline Bio Investor Relations Material
Latest events
Study Update
Tourmaline Bio
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tourmaline Bio Inc
Access all reports
Tourmaline Bio Inc. is a biotechnology company focused on developing treatments for immune and inflammatory diseases. The company is engaged in the late-stage clinical development of therapies aimed at significantly improving the lives of patients with severe autoimmune and inflammatory conditions. Its product pipeline includes medicines designed to address conditions such as atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company is headquartered in New York, NY, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
TRML
Country
🇺🇸 United States